FDA reviewers back approval of Bayer's lung drug at lower doses

08/4/2013 | Reuters

The FDA should approve Bayer's experimental pulmonary hypertension drug riociguat but at lower doses than what the company sought, the agency's medical reviewers said. The drug, which will be marketed as Adempas once approved, is designed to enhance the exercise ability of patients with chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ